he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源IP
- 2022-05-05医学的进步还是药企的福利?科学杂志还击糖尿病前期概念的是与非
- 2022-04-25进军主流免疫治疗
- 2022-04-212013年国际间抗癫痫联合会抗癫痫药使用指南
- 2022-04-13继发性痛经和原发性痛经有什么区别?
- 2022-04-12银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 2022-04-11贝安健康:常见的妇科炎症有哪些类型?
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 贝安健康:常见的妇科炎症有哪些类型?
- 检测和监测老龄化症状有新的工具
- 女性附件炎的常见症状是什么?
- 私密┃月经结束了。内衣上这些棕色的东西是什么?
- 如何借助莲藕健康?SaaS,实现DTC医药数字营销?
- 霉菌性阴炎来月经怎么治疗?
- 青光眼五大症状有哪些?
- 与甘精胰岛素相比,礼来替西帕肽能显著降低糖化血红蛋白(A1c)水平
- 疼痛 检查被男医生要求这样做
- 癫痫诊断的依据是什么?
- 扬子江药业评价信息:同日两品种获批上市!今年,共有86个品种的评价
- J Urol:在性腺功能减退患者中,肌内注射丙酸睾酮和皮射庚酸睾酮哪种效果好?
- 流血不简单!子宫内膜出血怎么了?
- 甲硝唑 VS 替硝唑,只是一字之差吗?
- 女性子宫的功能是什么?
- 炎症的原因是什么?
- 合肥京东方医院泌尿科成功减少肥大增生患者「肥」
- 治疗类风湿性关节炎/膝骨关节炎的专家共识
- Pancreatology: 过去糖尿病与急性胰腺炎的严重程度之间的关系
- J Allergy Clin Immunol:IgE对鼻息肉有影响吗?
- 钙化 = 结石?看医生怎么说?
- 一例低流量血管畸形
- Sci Rep:可能参与睾丸生理调节
- 炎能根治吗
- FDA 授予 Venetoclax 第三突破性治疗药物资格
- 外阴炎的原因是什么?
- 沈阳癫痫病医院治疗款项是多少
- 孕妇癫痫病会情况严重吗
- 脑炎后遗症 治疗脑炎后遗症的工具有哪些
- 胶质母细胞瘤能治愈吗?盘点七大前沿病人进展
- 痫病的治疗方式是什么 痫病有这些偏方
- 广州癫痫性疾病医院排名|小儿癫痫有哪些典型性疾病状
- 继发性脑瘤能治愈吗 治疗脑瘤有这几个步骤
- 类亨廷顿病综合征辨识诊断的7种临床特点
- 癫痫病的治疗开销
- 病征性癫痫病治疗需要多少钱
- 绝食疗法 什么是绝食疗法
- 癫痫高血压需要反复检查脑电图的原因
- 20120816cctv10健康之路:周文静揭秘脑部骨架